306 related articles for article (PubMed ID: 35657483)
1. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
Perera ND; Mansfield AS
Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
Nowak AK; Chin WL; Keam S; Cook A
Lung Cancer; 2021 Dec; 162():162-168. PubMed ID: 34823106
[TBL] [Abstract][Full Text] [Related]
3. Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.
Assié JB; Jean D
Expert Opin Ther Targets; 2023; 27(11):1059-1069. PubMed ID: 37902459
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
5. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
Hu ZI; Ghafoor A; Sengupta M; Hassan R
Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
[TBL] [Abstract][Full Text] [Related]
6. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
7. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy approaches for malignant pleural mesothelioma.
Fennell DA; Dulloo S; Harber J
Nat Rev Clin Oncol; 2022 Sep; 19(9):573-584. PubMed ID: 35778611
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
Borgeaud M; Kim F; Friedlaender A; Lococo F; Addeo A; Minervini F
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902544
[TBL] [Abstract][Full Text] [Related]
11. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
12. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
13. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D
Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
[No Abstract] [Full Text] [Related]
14. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
15. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
[TBL] [Abstract][Full Text] [Related]
16. Improvements in Systemic Therapies for Advanced Malignant Mesothelioma.
Deiana C; Fabbri F; Tavolari S; Palloni A; Brandi G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445594
[TBL] [Abstract][Full Text] [Related]
17. What's Current and What's New in Mesothelioma?
Leal JL; Hoang W; Xue J; Dunne B; John T; Harden S
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):771-780. PubMed ID: 36155156
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
20. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
